Permar, Sallie RFong, YouyiVandergrift, NathanFouda, Genevieve GGilbert, PeterParks, RobertJaeger, Frederick HPollara, JustinMartelli, AmandaLiebl, Brooke ELloyd, KrisseyYates, Nicole LOverman, R GlennShen, XiaoyingWhitaker, KaylanChen, HaiyanPritchett, JamieSolomon, ErikaFriberg, EmmaMarshall, Dawn JWhitesides, John FGurley, Thaddeus CVon Holle, TarraMartinez, David RCai, FangpingKumar, AmitXia, Shi-MaoLu, XiaozhiLouzao, RaulWilkes, SamanthaDatta, SaheliSarzotti-Kelsoe, MarcellaLiao, Hua-XinFerrari, GuidoAlam, S MunirMontefiori, David CDenny, Thomas NMoody, M AnthonyTomaras, Georgia DGao, FengHaynes, Barton F2016-06-012015-07-01https://hdl.handle.net/10161/12060Despite the wide availability of antiretroviral drugs, more than 250,000 infants are vertically infected with HIV-1 annually, emphasizing the need for additional interventions to eliminate pediatric HIV-1 infections. Here, we aimed to define humoral immune correlates of risk of mother-to-child transmission (MTCT) of HIV-1, including responses associated with protection in the RV144 vaccine trial. Eighty-three untreated, HIV-1-transmitting mothers and 165 propensity score-matched nontransmitting mothers were selected from the Women and Infants Transmission Study (WITS) of US nonbreastfeeding, HIV-1-infected mothers. In a multivariable logistic regression model, the magnitude of the maternal IgG responses specific for the third variable loop (V3) of the HIV-1 envelope was predictive of a reduced risk of MTCT. Neutralizing Ab responses against easy-to-neutralize (tier 1) HIV-1 strains also predicted a reduced risk of peripartum transmission in secondary analyses. Moreover, recombinant maternal V3-specific IgG mAbs mediated neutralization of autologous HIV-1 isolates. Thus, common V3-specific Ab responses in maternal plasma predicted a reduced risk of MTCT and mediated autologous virus neutralization, suggesting that boosting these maternal Ab responses may further reduce HIV-1 MTCT.AIDS VaccinesAntibodies, NeutralizingAntibody SpecificityAntigens, ViralCohort StudiesFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunoglobulin GInfantInfant, NewbornInfectious Disease Transmission, VerticalLogistic ModelsMultivariate AnalysisPeptide FragmentsPregnancyPregnancy Complications, InfectiousRisk FactorsJournal article1558-8238